🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — June 08, 2026

The IPO pipeline on June 8, 2026, is dominated by three new SPAC filings (AParadise II, Research Alliance Corp IV, and Cartesian Growth Corp IV) collectively seeking to raise $635 million, signaling a resurgence in blank-check activity despite a challenging regulatory environment. Among the three follow-on filings, AIM ImmunoTech, HCW Biologics, and Agape ATP Corp all exhibit mixed sentiment due to operational risks, Nasdaq compliance issues, and uncertain capital structures. Period-over-period data reveals Agape ATP Corp narrowing its net loss by 52% YoY in Q1 2026, while AIM ImmunoTech and HCW Biologics show no revenue from approved products, relying on warrant exercises for potential cash. Insider activity is absent across all filings, but forward-looking statements highlight key catalysts: AIM's planned Phase 3 pancreatic cancer trial with Thermo Fisher, HCW's Phase 1 alopecia areata data, and Agape's unresolved $24.1M investment deposit. The most critical developments are the SPACs' lack of identified targets, which creates binary risk, and the biotech firms' reliance on regulatory approvals and Nasdaq compliance deadlines. Portfolio-level patterns include a concentration of high-risk, pre-revenue companies in the follow-on space and a return of large SPAC IPOs targeting $250M+ raises.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — June 08, 2026

The June 8, 2026, filing stream reveals a market bifurcated between aggressive capital restructuring and fundamental operational stress. The most critical event is the Chapter 11 filing by Silver Star Properties REIT (Materiality 10/10), signaling severe distress in commercial real estate, while GoHealth's prepackaged Chapter 11 (Materiality 9/10) highlights a strategic debt restructuring that will wipe out common equity. A wave of reverse mergers and SPAC deals is reshaping the small-cap landscape, with SUNation Energy's acquisition of Suniva (Materiality 9/10) creating a dominant U.S. solar cell manufacturer but diluting existing SUNE shareholders by 98.2%. On the positive side, Nurix Therapeutics' $700M upfront Roche collaboration (Materiality 9/10) and Bending Spoons' 237% revenue growth over two years (Materiality 9/10) represent standout opportunities in biotech and tech, respectively. Period-over-period trends show a mixed picture: Aeries Technology swung to profitability but on flat revenue, while FuelCell Energy's losses widened 103% YoY due to a $42.6M impairment. Portfolio-level patterns indicate a surge in debt financing (MSD Investment Corp tripling its unsecured debt limit to $600M, Ares Capital's $1B CP program) and a concerning number of insolvency/restructuring filings (Future Lifestyle, PS IT, Future Consumer, Silver Star, GoHealth). Insider activity is notably absent from most filings, but the board removals at Pangaea Logistics and the mass resignation of Jordan Krugman from five Invesco entities signal governance instability.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — June 08, 2026

The 21 filings reveal a deeply bifurcated earnings landscape. While top-line growth is present in several names (GRAHAM CORP +17%, Elastic N.V. +17%, Mama's Creations +49.7%), it is often masking underlying margin compression or one-time benefits. A significant cluster of companies is reporting widening net losses or sharp profit declines, driven by impairment charges (FuelCell Energy, Columbus McKinnon), transaction costs (Mission Produce), and rising R&D (Seaport Therapeutics). The most critical development is the prevalence of 'mixed' sentiment (12 of 21 filings), indicating that even companies with revenue growth face headwinds from cost inflation, cash burn, or balance sheet deterioration. Portfolio-level patterns show a clear divide: capital-intensive and industrial names are struggling with debt and impairments, while select consumer and tech firms are demonstrating genuine operational leverage. Insider activity is notably absent from the enriched data, but forward-looking guidance from GRAHAM CORP (+16-20% revenue growth) provides a key catalyst to watch.

21 high priority 21 total filings
· daily

US SEC Trading Suspension Halt Orders — June 08, 2026

The single filing in this intelligence stream, from aTyr Pharma, highlights a critical delisting risk due to non-compliance with Nasdaq's minimum bid price rule. The company has received a second 180-day compliance period, extending the deadline to November 30, 2026, but there is no assurance of success. The negative sentiment and high materiality score (8/10) underscore the severity of the situation for shareholders. No period-over-period comparisons, insider activity, or forward-looking guidance were available in the enriched data, limiting the depth of trend analysis. The key development is the company's failure to meet the initial deadline and its reliance on a second grace period, which introduces significant uncertainty. The market implication is a heightened risk of a sudden trading suspension and potential delisting, which would severely impact liquidity and valuation.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 08, 2026

This intelligence stream reveals a bifurcated corporate landscape: a wave of distressed companies is resorting to dilutive financing, reverse mergers, and Chapter 11 filings to survive, while a separate cohort of fundamentally sound firms is aggressively accessing capital markets for growth and acquisitions. The most critical developments include three bankruptcy filings (GoHealth, Silver Star Properties, and a prepackaged restructuring) and multiple going-concern warnings signaled by dilutive offerings and debt restructurings. Key period-over-period trends from the data show a stark contrast: Village Farms' revenue grew 15% YoY while Cerus increased its debt load by $5M, and FICO's $2B buyback signals confidence versus Volato's speculative pivot. A portfolio-level pattern emerges in the energy and solar sectors, where SUNation's reverse merger and Vivakor's $108M annualized crude oil deal highlight a push for scale and revenue diversification. The most actionable intelligence lies in tracking the 5 companies with imminent bankruptcy risks and the 3 companies with significant capital allocation events that could drive shareholder value.

48 high priority 48 total filings
· daily

US Executive Officer Management Changes SEC — June 08, 2026

This intelligence stream covering 50 filings from June 8, 2026, reveals a surge in executive leadership changes across sectors, with a notable bias toward CFO appointments and unexpected departures. Key themes include orderly succession planning in large caps (Lennar, Farmer Mac, First Watch) contrasted with abrupt exits driven by personal conduct (Perrigo CEO) and governance overhauls (Pangaea Logistics removed three directors). Insider activity is sparse, but capital allocation signals are mixed—Knightscope's aggressive incentive plan ($65M market cap awards) contrasts with the risk of dilution at Savara (601M authorized shares). Forward-looking data reveals a muted growth outlook: Perrigo reaffirmed net sales decline of up to 5.5%, while Clarivate reaffirmed 2026 guidance. Sector-wise, real estate (Equity Residential/AvalonBay merger) and biotech (Ionis board refresh) show consolidation for scale. Period-over-period comparisons are limited in these filings, but equity plan approvals with notable opposition (MetaVia 13.0% against reverse split, Avalo Therapeutics ESPP with 6.6M against) signal shareholder vigilance. The intelligence suggests portfolio focus on companies with stable transitions and tangible performance metrics, while flagging governance risk and dilution events.

50 high priority 50 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — June 08, 2026

The two bankruptcy filings on June 8, 2026, reveal a bifurcated distress landscape: one prepackaged, consensual restructuring (GoHealth) versus an emergency, contested filing (Silver Star Properties REIT). GoHealth’s filing is a structured balance sheet cleanup with 100% lender support, aiming for a quick emergence before the 2026 enrollment period, but it destroys common equity value and triggers a Nasdaq delisting. Silver Star’s filing is a reactive, high-urgency Chapter 11 driven by four loan defaults totaling $65.2 million and an imminent foreclosure on a $5.75 million promissory note, signaling severe liquidity crisis. Period-over-period comparisons are not explicitly available in the raw filings, but the contrast in preparation—GoHealth’s prepackaged consensus vs. Silver Star’s last-minute filing—highlights a key trend: companies with lender alignment can preserve operational continuity, while those without face asset fire sales. The materiality is extreme (9/10 and 10/10), with immediate implications for equity holders, creditors, and sector sentiment in healthcare services and specialty REITs.

2 high priority 2 total filings
· daily

US Corporate Board Director Changes SEC Filings — June 08, 2026

This batch of 50 filings reveals a significant wave of board and C-suite changes across US-listed companies, with notable patterns of insider departures, governance shake-ups, and strategic appointments. The most critical development is the abrupt resignation of Perrigo's CEO due to a code of conduct violation, a high-materiality event that introduces immediate leadership uncertainty despite reaffirmed guidance. A cluster of seven Invesco-related filings signals a coordinated, non-financial departure of a key executive across multiple funds, suggesting a routine internal restructuring. The Pangaea Logistics board removal of three directors and the Twenty One Capital director appointment following Tether's acquisition of SoftBank's stake highlight governance instability and strategic shifts. On a positive note, several companies are strengthening their boards with high-caliber independent directors, including 3M adding Cummins' CEO and Truist adding a former Bank of America vice chair. The upcoming Equity Residential/AvalonBay merger of equals is a transformative event, with a combined enterprise value of ~$69 billion. Overall, the period is characterized by active leadership transitions, with a mix of routine departures, strategic promotions, and a few high-concern events that warrant close monitoring.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — June 08, 2026

The June 8, 2026, US M&A stream reveals a bifurcated SPAC market: high-quality targets (Quantum Space, General Fusion) command complex deal structures and extended timelines, while smaller SPACs (New Providence, Patriot) rely on working capital loans and over-allotment exercises to bridge to a business combination. The most material development is Inflection Point's definitive agreement with Quantum Space, creating a pure-play space infrastructure company via an Up-C structure with dual-class voting, signaling strong sponsor conviction despite undisclosed valuation. Bluerock Homes Trust's disposition of 24 single-family units for $8.5M provides modest balance sheet relief but fails to address a persistent net loss of $9.5M, highlighting the ongoing operational challenges in the single-family rental sector. Keystone Acquisition Corp.'s $250M IPO targeting high-growth sectors (energy transition, digital assets) underscores continued institutional appetite for blank-check vehicles, while FG Merger II Corp.'s redemption deadline passing without disclosure of redemption levels creates uncertainty around BOXABL's post-combination cash position. No period-over-period revenue or margin trends are available as all filings are transactional 8-Ks, but capital allocation patterns (working capital loans, over-allotment exercises, asset sales) indicate a market where SPACs are actively managing liquidity to complete de-SPAC transactions.

8 high priority 8 total filings
· monthly

US Pre-Market SEC Filings Roundup — June 08, 2026

Overnight filings reveal a bifurcated market landscape: aggressive corporate restructurings and balance sheet maneuvers dominate, while select companies signal strong operational turnarounds and strategic pivots. Key themes include a wave of debt restructuring and bankruptcy filings (GoHealth, Silver Star Properties), significant M&A and partnership activity (Nurix/Roche $700M upfront, SUNation/Suniva reverse merger, Ciena $2B notes), and a notable number of shareholder compensation 'say-on-pay' failures (nLIGHT, Energy Recovery). Period-over-period data shows a sharp turnaround at Aeries Technology (swinging to $3.5M net income from -$21.6M loss) and Noble Romans (to $1.2M net income from -$3K loss), though revenue growth remains flat or negative for many. Insider activity is sparse, but capital allocation actions (Ciena buyback, Ares Capital CP program) provide positive signals. The most critical developments are the GoHealth and Silver Star bankruptcies, which signal distress in specific sectors, and the transformative Nurix-Roche deal, which validates the targeted protein degradation space.

25 high priority 25 medium 50 total filings
· daily

New Federal Contractors — June 06, 2026

This single-contract digest covers a $83.8 million civilian award from the Department of State to Cayuse Technologies, LLC, a tribally owned 8(a) small business, for design engineering and integration services through 2027. The contract is non-competitive (sole-source under the 8(a) program), providing a strong competitive moat but carries medium execution risk due to its firm-fixed-price structure and the absence of any prior outlays. The highest-conviction signal is the near-term revenue visibility of $15.2 million annually, though investors should watch for the timing of first outlays to confirm contract execution. There are no defense-related contracts in this period, underscoring a civilian-focused, set-aside-driven award pattern.

1 total filings
· daily

Significant Contract Modifications ($10M+) — June 06, 2026

This digest covers a single, large civilian contract modification from the Department of State to Cayuse Technologies, LLC, valued at $83.8 million. The award is non-competitive under the 8(a) program, signaling a strong competitive moat for the tribally owned small business. The contract is firm-fixed-price, transferring cost risk to the contractor, and has no prior outlays, introducing execution risk. The highest-conviction signal is the sole-source advantage, but the lack of defense exposure and the fixed-price structure temper the bullish outlook. Key watch items include the timing of first outlays and option exercise announcements to confirm program execution.

1 total filings
· daily

Contract Deobligations Alert — June 06, 2026

The single contract deobligation alert for June 6, 2026, totals $83.8 million, entirely civilian (Department of State) with no defense exposure. The dominant signal is a bullish sole-source 8(a) award to Cayuse Technologies, LLC, a tribally owned small business, for design engineering and integration services through 2027. The $83.8 million base obligation provides strong near-term revenue visibility, but the firm-fixed-price structure transfers cost risk to the contractor, and the absence of prior outlays introduces execution risk. Key watch items include the timing of first outlays and option exercise announcements to confirm contract performance and client satisfaction.

1 total filings
· daily

Contract Option Exercises — June 06, 2026

The single contract option exercise in this period represents a $83.8 million civilian award from the Department of State to Cayuse Technologies, LLC, a tribally owned small business. This is a non-competitive 8(a) set-aside, signaling strong policy-driven spending but limited competitive validation. The firm-fixed-price structure transfers cost risk to Cayuse, while the 5.5-year performance period offers long-term revenue visibility. The highest-conviction signal is the sole-source advantage under the 8(a) program, which provides a durable competitive moat. A key risk is the absence of any prior outlays, introducing execution uncertainty despite the large base obligation. This is a purely civilian contract with no defense exposure, making it less sensitive to NDAA or CR dynamics but more tied to State Department IT modernization budgets.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — June 06, 2026

The sole Federal IT & Cybersecurity contract analyzed for June 6, 2026, is a $83.8 million Department of State award to Cayuse Technologies, LLC, a tribally owned 8(a) small business. This civilian-agency contract represents 100% of the period’s total obligation and carries a bullish signal (strength 7/10) due to its sole-source competitive moat and long-duration fixed-price structure. However, the absence of prior outlays and the firm-fixed-price risk transfer to Cayuse introduce execution uncertainty. Investors should monitor first outlay timing and option exercises as key catalysts for revenue visibility.

1 total filings
· daily

High-Value Federal Grants ($5M+) — June 06, 2026

The single high-value contract in this period, an $83.8 million non-competitive 8(a) award from the Department of State to Cayuse Technologies, LLC, underscores a civilian-agency IT modernization theme with a tribal small-business set-aside angle. The award is bullish for Cayuse’s near-term revenue visibility, but the firm-fixed-price structure and zero prior outlays introduce execution risk. With no defense-related contracts, the digest signals a civilian-sector opportunity concentrated in State Department spending. The highest-conviction signal is the sole-source 8(a) competitive moat, while the key watch item is the timing of first outlays to confirm contract ramp.

1 total filings
· daily

General Federal Contracts — June 06, 2026

The single contract awarded during this period, an $83.8 million firm-fixed-price deal to Cayuse Technologies, LLC from the Department of State, represents a purely civilian-sector win with no defense exposure. The award, made non-competitively under the 8(a) program, signals a strong competitive moat for Cayuse but carries execution risk due to the fixed-price structure and zero prior outlays. The highest-conviction signal is the sole-source advantage and long-term revenue visibility through January 2027, though the absence of any disbursements to date is a key watch item. This digest highlights a concentrated civilian IT modernization theme with limited near-term cash flow visibility.

1 total filings
· daily

Biotech Small-Cap Approvals — June 05, 2026

This digest covers 14 FDA approvals from May 29 to June 5, 2026, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 14 'Other' approvals, predominantly generic/biosimilar entries for established molecules. The dominant theme is generic competition in chronic disease and oncology support drugs, with three separate tofacitinib citrate approvals from Somerset Ther., Aurobindo, and Sun Pharma signaling imminent erosion of Pfizer’s Xeljanz franchise. The highest-conviction bullish signal is ranibizumab-hkdz (RANLUSPEC) from Lupin, a novel biologic for retinal disease with strong commercial upside. The key risk is the lack of any NME approvals this period, underscoring a bearish near-term outlook for small-cap biotech innovation and pipeline value creation.

14 total filings
· daily

New Drug Approvals (Original) — June 05, 2026

This June 2026 approval period is dominated by a wave of generic/biosimilar entries, with 0 NMEs, 0 biosimilars (per classification), and 14 'Other' approvals, primarily FALLBACK-type generic authorizations. The highest-conviction signal is LUPIN LIMITED's approval of RANIBUZUMAB-HKDZ (RANLUSPEC), a biosimilar to Genentech/Roche's Lucentis in ophthalmology—a bullish event for LUPIN with significant revenue erosion potential for the originator. Additionally, CASPER PHARMA LLC's label expansion for TIOPRONIN (TIOCYSTIN) provides a niche bullish signal. Key risk: this period lacks high-value NME catalysts, and the 12 neutral approvals (including multiple tofacitinib citrate generics from SOMERSET, AUROBINDO, and SUN PHARMA) signal an escalating pricing war in the JAK inhibitor market, pressuring originator Xeljanz (Pfizer).

14 total filings
· daily

DHS Homeland Security Contracts — June 05, 2026

This digest covers a single $86.1 million DHS/Customs and Border Protection (CBP) contract awarded to ElbitAmerica, Inc., a subsidiary of Israel-based Elbit Systems Ltd, for border surveillance tower consolidation. The contract is entirely civilian (0% defense-related) and carries a moderate bullish signal (6/10 strength) due to its firm-fixed-price structure and competitive full-and-open award, indicating technical merit. The highest-conviction signal is the sustained DHS investment in border surveillance technology, but key risks include zero outlays to date and execution risk under fixed-price terms, as well as potential policy headwinds for foreign-owned contractors. Investors should monitor contract outlays and option exercises to validate revenue recognition and DHS budget commitment.

1 total filings